Abstract
Millions of people are afflicted with psoriasis, which is a chronic inflammatory skin disease throughout the world. Despite modern treatments for psoriasis remain unmet needs and challenges in achieving optimal results. This review article aims to present a multidimensional view of the research and therapy for psoriasis, which encompasses not only the cellular and molecular mechanisms but also the network pharmacology of traditional Chinese medicine, novel therapeutic targets and strategies as well as autophagy plays a role on psoriasis pathogenesis or treatment. At the same time discussion on bimekizumab, once was declared an initial proof of concept biological agent that acts by both inhibiting interleukin-17 A and F (two cytokines slightly different) in psoriasis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: INTERNATIONAL JOURNAL OF PHARMACEUTICAL QUALITY ASSURANCE
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
